NOVARTIS AG-SPONSORED ADR

NVSNYSE

Earnings Oct 27US Equity

$154.61▼ $2.15 (−1.39%)

Live

1h—

24h▼ 1.4%

7d—

14d—

30d—

1y—

🏦Market Cap

$314.60B

Large Cap

📈Revenue Growth (YoY)

+3.3%

Slowing

📊Gross Margin

75.0%

High

💵FCF Margin

26.4%

Strong

⚖️P/S Ratio

5.0x

Fair

Otter Score

Weak

No chart data available for NVS.

Trading Snapshot

Day Range: $152.41 – $157.00
52-Week Range: $91.56 – $131.50
Volume: $3.41B
Avg Volume: $2.91B
Shares Outstanding: 2.03B
Next Earnings: Oct 3, 2026

Fundamentals Snapshot

Annual Revenue: $54.81B
Last Q Revenue: $14.42B
P/E Ratio: 22.4
P/S Ratio: 5.0x
EPS (TTM): $6.62
Dividend Yield: 3.18%

Why Investors Own NVS

✓High-growth profile — revenue up +9.0% YoY with expanding US Equity exposure.
✓Healthy economics — 77% gross margin and 26% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$54.81B▲ +13.0% YoY

Gross Margin (TTM)

76.9%▲ +4.1% YoY

Operating Income (TTM)

$6.14B▲ +13.0% YoY

Free Cash Flow (TTM)

$14.42B▲ +13.0% YoY

About NOVARTIS AG-SPONSORED ADR

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

🦦